Philogen S.p.A.

Equities

PHIL

IT0005373789

Biotechnology & Medical Research

Market Closed - Borsa Italiana Other stock markets 09:14:59 17/05/2024 pm IST			5-day change	1st Jan Change
18 ^EUR	0.00%		0.00%	-2.70%

07/05	Philogen, NFP and liquidity drop in first quarter	AN
12/04	Indices up; Italy, industrial sales down	AN

Philogen S p A : is delighted to invite you to attend a virtual briefing on April 3, 2024 to discuss the Company’s Full Year 2023 Results.

April 05, 2024 at 08:42 pm IST

2024, Events, Investors

Philogen is delighted to invite you to attend a virtual briefing on April 3, 2024 to discuss the Company's Full Year 2023 Results.

Apr 3, 2024

Management will host a 1-hour live webcast and conference call on April 3, 2024 at 10:00 ET / 15:00 BST / 16:00 CET.

The presentation will be followed by a Q&A session.

Please follow the link here to register to the event or contact us at ir@philogen.com.

Attachments

Original Link
Permalink

Disclaimer

Philogen S.p.A. published this content on 03 April 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 05 April 2024 15:11:06 UTC.

Latest news about Philogen S.p.A.

Philogen, NFP and liquidity drop in first quarter	07/05	AN
Indices up; Italy, industrial sales down	12/04	AN
Transcript : Philogen S.p.A., 2023 Earnings Call, Apr 03, 2024	03/04
Philogen reduces loss in 2023; NFP remains positive	27/03	AN
Philogen S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03	CI
Mib re-emerges in green; Saipem resumes rally	07/03	AN
Futures await lists in red	27/02	AN
Europeans down; Sogefi flies in Piazza Affari.	26/02	AN
Philogen S.p.A. Provides Update on Pre-Planned Interim Analysis of the Phase III FIBROSARC Trial Investigating Onfekafusp Alfa in Patients with First-Line Advanced or Metastatic Soft Tissue Sarcoma	20/02	CI
Mib in the red at 31,600; TIM still on top	19/02	AN
European indexes down; TIM tops Mib	19/02	AN
Futures bullish; PMI data coming in.	24/01	AN
Mib gives ground; Saipem resists declines	23/01	AN
Mib loses 30,000 points; MPS shines	17/01	AN
Mib falls below 30,400; Amplifon tops	08/01	AN
Piazza Affari down slightly; banks on the Mib do well	08/01	AN
Philogen S.P.A. Announces Receipt of the Good Manufacturing Practice Certificate for Its New Production Facility in Rosia (Siena, Italy) by Competent Authorities	05/12	CI
Cucinelli on Mib in December; Philogen, d'Amico and SAES on Mid	23/11	AN
Philogen, net financial position falls in third quarter	08/11	AN
Philogen has purchased 3,300 shares of its own common stock	23/23/23	AN
Transcript : Philogen S.p.A. - Special Call	18/23/18
Philogen purchased 10,400 shares of its own common stock	17/23/17	AN
Philogen S.P.A. and Sun Pharmaceutical Industries Limited Announces Positive Results from the Phase III Pivotal Trial in Patients with Locally Advanced Fully Ressectable Melanoma	16/23/16	CI
Philogen announces positive Phase III results for Nidlegy	16/23/16	AN
Philogen purchased approximately 8,000 shares of its own common stock	09/23/09	AN

Chart Philogen S.p.A.

Duration

Period

More charts

Company Profile

Philogen SpA is an Italy-based company, operating in the biotechnology sector. The Company develops products and technologies for the diagnosis and therapy of serious human diseases. It has three anti-cancer antibody derivatives, produced with an in-house industrial process, into Phase I/II clinical studies. The majority of its technologies and products are based on high-affinity human monoclonal antibody fragments. Philogen SpA developed a patented technology, Iterative Colony Filter Screening, for the isolation of monoclonal antibodies, which requires neither immunization nor phage display. The Company's subsidiaries are Philotec, Philomed and Philochem. Philogen SpA is headquartered in Siena, Italy.

Sector

Biotechnology & Medical Research

Calendar

08/06/2024 - Chemical Biology Conference

More about the company

Income Statement Evolution

More financial data

Ratings for Philogen S.p.A.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

18 EUR

Average target price

23.5 EUR

Spread / Average Target

+30.56%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
PHILOGEN S.P.A.	-2.70%	79Cr
VERTEX PHARMACEUTICALS INCORPORATED	+9.01%	11TCr
REGENERON PHARMACEUTICALS, INC.	+11.42%	10TCr
BIONTECH SE	-12.38%	2.24TCr
ARGENX SE	-1.05%	2.23TCr
GENMAB A/S	-5.29%	1.91TCr
WUXI APPTEC CO., LTD.	-38.29%	1.8TCr
BEIGENE, LTD.	-2.76%	1.79TCr
NEUROCRINE BIOSCIENCES, INC.	+8.07%	1.43TCr
SAREPTA THERAPEUTICS, INC.	+34.99%	1.25TCr

Bio Therapeutic Drugs